FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096586542> ?p ?o ?g. }

• W2096586542 endingPage "174" @default.
• W2096586542 startingPage "174" @default.
• W2096586542 abstract "Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma (HCC) in patients chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). The approved medication for the treatment of chronic HBV infection is interferon-α (IFNα) and nucleos(t)ide analogues (NAs), including lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir disoproxil fumarate. IFNα is the most suitable for young patients with less advanced liver diseases and those infected with HBV genotype A. IFNα treatment significantly decreases the overall incidence of HBV-related HCC in sustained responders. However, side effects may limit its long-term clinical application. Orally administered NAs are typically implemented for patients with more advanced liver diseases. NA treatment significantly reduces disease progression of cirrhosis and therefore HCC incidence, especially in HBV e antigen-positive patients. NA-resistance due to the mutations in HBV polymerase is a major limiting factor. Of the NA resistance-associated mutants, A181T mutant significantly increases the risk of HCC development during the subsequent course of NA therapy. It is important to initiate treatment with NAs that have a high genetic barrier to resistance, to counsel patients on medication adherence and to monitor virological breakthroughs. The recommended treatment for patients with chronic HCV infection is peg-IFN plus ribavirin that can decrease the occurrence of HCC in those who achieve a sustained virological response and have not yet progressed to cirrhosis. IFN-based treatment is reserved for patients with decompensated cirrhosis who are under evaluation of liver transplantation to reduce post-transplant recurrence of HCV. More effective therapeutic options such as direct acting antiviral agents will hopefully increase the response rate in difficult-to-treat patients with HCV genotype 1. However, the risk of HCC remains in cirrhotic patients (both chronic HBV and HCV infection) if treatment is initiated after cirrhosis is established. Future research should focus on investigating new agents, especially for those patients with hepatic decompensation or post-transplantation." @default.
• W2096586542 created "2016-06-24" @default.
• W2096586542 creator A5005201474 @default.
• W2096586542 creator A5016839056 @default.
• W2096586542 creator A5022193491 @default.
• W2096586542 creator A5045434815 @default.
• W2096586542 creator A5049464184 @default.
• W2096586542 creator A5053528169 @default.
• W2096586542 creator A5072964389 @default.
• W2096586542 date "2012-01-01" @default.
• W2096586542 modified "2023-09-25" @default.
• W2096586542 title "Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma" @default.
• W2096586542 cites W1481292409 @default.
• W2096586542 cites W1491713498 @default.
• W2096586542 cites W1605771536 @default.
• W2096586542 cites W1758726432 @default.
• W2096586542 cites W1964039671 @default.
• W2096586542 cites W1965962200 @default.
• W2096586542 cites W1966398441 @default.
• W2096586542 cites W1976104517 @default.
• W2096586542 cites W1980095859 @default.
• W2096586542 cites W1983154697 @default.
• W2096586542 cites W1983364530 @default.
• W2096586542 cites W1984897642 @default.
• W2096586542 cites W1985152776 @default.
• W2096586542 cites W1988980065 @default.
• W2096586542 cites W1996865638 @default.
• W2096586542 cites W1998416778 @default.
• W2096586542 cites W2003244782 @default.
• W2096586542 cites W2004054613 @default.
• W2096586542 cites W2004100607 @default.
• W2096586542 cites W2004832653 @default.
• W2096586542 cites W2014495557 @default.
• W2096586542 cites W2014837723 @default.
• W2096586542 cites W2015740979 @default.
• W2096586542 cites W2019596061 @default.
• W2096586542 cites W2022226503 @default.
• W2096586542 cites W2025524023 @default.
• W2096586542 cites W2029879555 @default.
• W2096586542 cites W2042033552 @default.
• W2096586542 cites W2042565956 @default.
• W2096586542 cites W2047489750 @default.
• W2096586542 cites W2049402010 @default.
• W2096586542 cites W2051976356 @default.
• W2096586542 cites W2052276375 @default.
• W2096586542 cites W2055339444 @default.
• W2096586542 cites W2058376942 @default.
• W2096586542 cites W2061505027 @default.
• W2096586542 cites W2061743943 @default.
• W2096586542 cites W2062680879 @default.
• W2096586542 cites W2063285149 @default.
• W2096586542 cites W2063392618 @default.
• W2096586542 cites W2064546869 @default.
• W2096586542 cites W2065099361 @default.
• W2096586542 cites W2068151431 @default.
• W2096586542 cites W2069309210 @default.
• W2096586542 cites W2070310839 @default.
• W2096586542 cites W2073513838 @default.
• W2096586542 cites W2088305891 @default.
• W2096586542 cites W2090439540 @default.
• W2096586542 cites W2091377367 @default.
• W2096586542 cites W2093208686 @default.
• W2096586542 cites W2093946039 @default.
• W2096586542 cites W2095010714 @default.
• W2096586542 cites W2097820722 @default.
• W2096586542 cites W2104389844 @default.
• W2096586542 cites W2106787323 @default.
• W2096586542 cites W2108639262 @default.
• W2096586542 cites W2113864802 @default.
• W2096586542 cites W2117766751 @default.
• W2096586542 cites W2119764771 @default.
• W2096586542 cites W2122853284 @default.
• W2096586542 cites W2126446476 @default.
• W2096586542 cites W2126475597 @default.
• W2096586542 cites W2132846960 @default.
• W2096586542 cites W2137349173 @default.
• W2096586542 cites W2143558957 @default.
• W2096586542 cites W2144084705 @default.
• W2096586542 cites W2147133758 @default.
• W2096586542 cites W2147261885 @default.
• W2096586542 cites W2147292430 @default.
• W2096586542 cites W2156015715 @default.
• W2096586542 cites W2162569070 @default.
• W2096586542 cites W2163240479 @default.
• W2096586542 cites W2163577777 @default.
• W2096586542 cites W2163606686 @default.
• W2096586542 cites W2168076454 @default.
• W2096586542 cites W2168177532 @default.
• W2096586542 cites W2168729724 @default.
• W2096586542 cites W2171945301 @default.
• W2096586542 cites W2420419190 @default.
• W2096586542 cites W3030265267 @default.
• W2096586542 cites W3150298192 @default.
• W2096586542 cites W4239670970 @default.
• W2096586542 cites W4243625103 @default.
• W2096586542 doi "https://doi.org/10.5501/wjv.v1.i6.174" @default.
• W2096586542 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3782279" @default.
• W2096586542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24175223" @default.

• next